Long COVID Trial, Recruiting (NCT05890612)

Long COVID Trial, Recruiting NCT05890612 Sponsor: Pfizer Condition: Long COVID

Printed from Voxsanity (voxsanity.com.au) — NCT05890612 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Long Covid

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have already taken, are currently taking, or are planning to take PAXLOVID as approved for use in your country.
You (or a legal representative on your behalf) are willing to sign a consent form before joining the study.

Who may not be able to join:

You have a medical reason that means you should not take PAXLOVID, based on the approved guidelines in your country.
You are planning to take any other experimental or investigational medicine during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05890612

Sponsor: Pfizer

Phase: Not Applicable

Status: Recruiting

Condition: Long COVID

Trial contact: 1-800-718-1021

More information: https://clinicaltrials.gov/study/NCT05890612

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have already taken, are currently taking, or are planning to take PAXLOVID as approved for use in your country.
You (or a legal representative on your behalf) are willing to sign a consent form before joining the study.

Who may not be able to join:

You have a medical reason that means you should not take PAXLOVID, based on the approved guidelines in your country.
You are planning to take any other experimental or investigational medicine during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Pfizer

Registry

ClinicalTrials.gov

Start date

29 November 2023

Est. completion

13 July 2029

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Proportion of patients with an adverse event (AE); Proportion of patients with an adverse drug reaction (ADR); Proportion of patients with a serious AE (SAE); Proportion of patients with a serious ADR (SADR); Proportion of patients with an unexpected AE (UAE); Proportion of patients with an unexpected ADR (UADR); Proportion of patients with a serious unexpected AE (SUAE); Proportion of patients with a serious unexpected ADR (SUADR); Proportion of COVID-19-related hospitalization from any cause; Proportion of COVID-19-related death from any cause; Proportion of subjective assessment of COVID-19...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov